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Abstract
Background: The plastic monomer and plasticizer bisphenol A (BPA), used for manufacturing polycarbonate plastic
and epoxy resins, is produced at over 2.5 million metric tons per year. Concerns have been raised that BPA acts as
an endocrine disruptor on both developmental and reproductive processes and a large body of evidence suggests
that BPA interferes with estrogen and thyroid hormone signaling. Here, we investigated BPA effects during
embryonic development using the zebrafish and Xenopus models.
Results: We report that BPA exposure leads to severe malformations of the otic vesicle. In zebrafish and in Xenopus
embryos, exposure to BPA during the first developmental day resulted in dose-dependent defects in otolith
formation. Defects included aggregation, multiplication and occasionally failure to form otoliths. As no effects on
otolith development were seen with exposure to micromolar concentrations of thyroid hormone, 17-ß-estradiol or
of the estrogen receptor antagonist ICI 182,780 we conclude that the effects of BPA are independent of estrogen
receptors or thyroid-hormone receptors. Na+/K+ ATPases are crucial for otolith formation in zebrafish.
Pharmacological inhibition of the major Na+/K+ ATPase with ouabain can rescue the BPA-induced otolith
phenotype.
Conclusions: The data suggest that the spectrum of BPA action is wider than previously expected and argue for a
systematic survey of the developmental effects of this endocrine disruptor.
Background
Bisphenols represent a group of industrial chemicals,
widely and abundantly used for the production of poly-
carbonate plastics and epoxy resins. The most common
bisphenol, bisphenol A [2,2-bis(4-hydroxyphenyl)pro-
pane; BPA] is used in the manufacture of plastic wares,
dental resins, food can lining and flame retardants.
Total annual production of BPA in the world exceeds
2.5 million metric tons [1]. Bisphenols may be present
in the environment as a result of direct release from
manufacturing or processing facilities or release of
unreacted monomers. According to the recent NTP
report total environmental release of BPA in 2004 was
82 tons [2]. BPA is among the most frequent organic
wastewater contaminants detected in ground water in
the USA [3]. In the United States, the median reported
BPA concentration in surface waters was 0.14 μg/L
whereas in Europe, mean values of 0.0047 μg/L and
0.0052 μg/L were observed in Germany and Netherlands
respectively [4-6]. However, BPA levels found in receiv-
ing waters near processing facilities can occasionally
reach levels higher than 20 μg/L [4]. The presence of
BPA in fish has been examined by several authors. Bash-
eer et al. found that BPA residues in the fish Decapterus
russelli from Singapore averaged 65.6 ng/g [7]. Concen-
trations ranging from 2 to 75 ng/g in the liver and from
1 to 11 ng/g in muscle were found in flounder (Pla-
tichthys flesus) and bream (Abramis brama) respectively.
These fish were collected from Dutch coastal waters [4].
The highest potential for human exposure to BPA is
through products that directly contact food like bever-
age containers with internal epoxy resin coatings, poly-
carbonate tableware and feeding bottles. Assessment of
human BPA exposure by biomonitoring urinary excre-
tion of BPA metabolites in the population gives an
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estimated average daily exposure of BPA up to 7 μg/
adult/day and up to 66 μg/day in six months old infants
(EFSA, 2006). Measurements of BPA in serum of adult
men and women show mean concentrations of 1.49 and
0.64 ng/mL respectively [8,9]. Presence of BPA was also
reported in maternal and fetal plasma, in placental tissue
in humans [10,11] and in the milk of nursing mothers
[12]. Most disquieting is the concentration of BPA in
amniotic fluid that is approximately five-fold higher
than levels measured in maternal plasma [10].
Several bisphenols have been shown to cause adverse
effects in vertebrates, including humans, by interfering
with normal endocrine function [13-16] and are thus
classified as endocrine disruptors (EDs). The available
data on the interactions between BPA and the endocrine
systems suggest it could trigger a wide variety of adverse
effects in vivo. BPA displays estrogenic activity in a
number of experimental systems and thereby has the
potential to adversely affect reproductive function and
development in humans and wildlife [17-19]. It can bind
to and act as a weak agonist on both estrogen receptors
ERa and ERb with affinity constants of 0.1 and 1 μM
respectively [20-22] but can also be an antagonist in
some type of cells via ERa [23]. Thus, it is defined as a
selective ER modulator [24]. In addition, data from
recent studies have revealed that low levels of BPA can
induce rapid, membrane-initiated effects similar to the
non-genomic effects induced by estrogen [25,26]. Thus,
BPA exposure could result in interference with normal
estrogenic signalling at multiple levels and at different
developmental stages as well as in the adult. In addition,
BPA has been shown to interact with other nuclear
receptor systems such as the thyroid hormone (TH)
receptors (TRs). BPA is a TR antagonist in transient
transfection assays in mammalian cells and BPA expo-
sure of rats during pregnancy causes an increase in
serum thyroid hormone concentration [27-29]. BPA acts
as a TR antagonist in a tail culture assay in Xenopus
[30]. Further, BPA inhibits T3-dependent responses in
an in vivo Xenopus embryo TH sensitive gene transcrip-
tion reporter assay [31]. All these data suggest that BPA
not only acts on the reproductive system via the estro-
gen receptors but can exert a wide range of actions
through various nuclear receptor targets during
development.
Little attention has been paid to the effects of BPA
during early developmental stages. Ramakrishnan and
Wayne showed that exposure to low levels of BPA
accelerated early embryonic development within 24h of
exposure, attenuated body growth and advanced the
times of hatching and reproductive maturation in
medaka fish (Oryzias latipes). It was also shown that
high dose of BPA exposure led to zebrafish embryo
mortality while sub-lethal doses led to no blood flow,
cardiac edema and tail malformation [32]. In the
medaka embryo, 200 microg BPA/l caused transient
embryonic deformities in medaka between days 4 and 8.
By day 9 BPA treated embryos were not different from
untreated siblings [33].
This lack of focus on early development may be due
in part to the fact that mammalian embryos are difficult
to access experimentally. A few recent papers have used
the free-living Xenopus laevis embryo to test the effects
of BPA at different stages of development [34,35]. In
particular, BPA was shown to cause malformations of
the head region including the eye [36]. We too chose to
exploit free-living embryos of Xenopus and zebrafish to
address the possibility that BPA might affect early devel-
opment and organogenesis. The advantage of using
aquatic embryos is the ease in adding substances to be
investigated to the aquarium water and study develop-
ment following exposure without requiring the injec-
tion/dissection of the mother as in mammalian models.
Furthermore, fish and amphibian embryos offer a
unique combination of advantages for studying genetics
and developmental biology during vertebrate organogen-
esis, as they are transparent, thereby allowing non-inva-
sive observation. In addition, the large numbers of
embryos per clutch provides large sample numbers. In
this paper, we report that BPA exposure during the first
days of embryonic life causes abnormalities of the inner
ear, both in zebrafish, and in Xenopus embryos. The use
of radioactive labeled bisphenols allowed us to deter-
mine the uptake of BPA and BPF and to estimate the
capability of the embryos to biotransform and eliminate
these xenobiotics. We found that the bio-concentration
factors were 27 and 11 for BPA and BPF respectively. In
addition we demonstrated that BPF but not BPA was
metabolized in the zebrafish embryo. We used pharma-
cological approaches to test whether BPA action was
linked to interferences with nuclear receptors such as
ER and TR and found that BPA is not acting through
these receptor systems during inner ear development. In
contrast, we observed that the Na+/K+ ATPase system is
required for BPA action. Our results thus reveal an
unanticipated effect of BPA during vertebrate embryonic
development.
Methods
Fish stocks
Breeding zebrafish of the AB-TU and TU wild type
strains were reared at 28.5°C and kept under a 8-hr
dark/16-hr light cycle and staged as described [37]. All
data were also obtained on the Konstanz wild type
strain with identical results. The development of endo-
genous pigments was inhibited by exposing embryos to
1-phenyl-2-thiourea (PTU) at a final concentration of
0.2 mM. This PTU treatment was not included in
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experiments designed to assess the effects of different
bispenols on pigmentation.
Treatment of zebrafish embryos
Embryos (5 hpf) were exposed for 1 to 2 days to BPA
(2,2-bis(4-hydroxyphenyl)propane, CAS No. 80-05-7), at
concentrations ranging from 10-8 M to 10-4 M, 17
b-estradiol (E2) (from 1 nM to 0.1 μM), ICI 182.780
(ICI) (from 1 μM to 50 μM), TH (up to 10-4 M), IOP
(iodopropanoic acid, 5. 10-3 M), PTU (5. 10-3) or oua-
bain (up to 2 mM) (Sigma) diluted in embryo medium,
from a stock solution in ethanol, DMSO or distilled
water. Wild type zebrafish treated by vehicule only were
used as negative controls to compare effects on com-
pound-treated zebrafish. Embryos (5 hpf) were also
exposed for 1 to 2 days to 5.10-5 M Bisphenol F (bis
(4-hydroxyphenyl)methane), 7. 10-5M Bisphenol E (bis
(4-hydroxyphenyl)ethane) and 10-6 M Bisphenol C (1,1-
Bis(4-hydroxyphenyl)-2,2-dichloroethylene) (Sigma),
diluted in embryo medium, from a 10-1 M stock solu-
tion in ethanol.
Measurement of BPA and BPF uptake and metabolism by
zebrafish embryos
[14C]-BPA, with a specific activity of 7.4 GBq.mmol-1
and a radio-purity greater than 99% was purchased from
Moravek Biochemicals (CA). [3H]-BPF, with a specific
activity of 300 MBq.mmol-1 and a radiopurity higher
than 99% was purchased from Izotop (Budapest, Hun-
gary). Zebrafish embryos (7 hpf, n=60 per group) were
exposed for 72 h to 5.10-5 M radiolabeled BPA, as
described above. At 18, 36 and 72 h, water (1 mL) and
embryos (3 pools of 4 individuals) were sampled sepa-
rately for radioactivity measurement. Embryos were
rinsed twice with E3 1X medium and weighed before
analysis. At the end of the experiment, remaining water
and embryos were collected separately and stored at
-20°C until radio-chromatography analysis. The same
experiment was repeated with radiolabeled BPF. The
radioactivity present in embryos was measured by liquid
scintillation counting with a Packard Tricarb 4430 coun-
ter after 90 min treatment at 60°C by 1 mL Soluene
(Packard Instruments Co., Meriden, CT). Radioactivity
in water was directly measured by liquid scintillation
counting. For all vials, sample quenching was compen-
sated by the use of quench curves and external standar-
disation. At the end of the experiment, remaining water
and embryos were collected separately and stored at
-20°C until radio-chromatography analysis. HPLC
coupled to online radioactivity detection (HP 1100
coupled to Flo-One A500 detector, with Flo-scint II as
scintillation cocktail, (Packard Instruments Co., Meri-
den, CT) was used for metabolite profiling. Water sam-
ples were evaporated to dryness and the residue was
dissolved in the HPLC mobile phase before analysis.
Radioactivity was extracted from pooled embryos with
acetonitrile. The organic fraction was evaporated to dry-
ness and redissolved in the HPLC mobile phase before
analysis. HPLC conditions were as described by Zalko
et al. [38] for BPA and by Cabaton et al. [39] for BPF.
In order to control the stability of tested compounds in
the medium, a blank, consisting of 50 mL embryo med-
ium and 5.10-5 M radiolabelled BPF or BPA was stored
during 72 h at 28.5°C before radio-HPLC analysis.
Treatment of Xenopus embryos
Groups of Xenopus embryos (n = 30 per group) at stage
NF 18 [40] were placed in six well plates with 15
embryos per well (well volume 10 mL) and exposed for
48 hours to BPA (5 or 10 μM) or solvent (DMSO 1 μL
in 10 mL). Xenopus embryos were left in contact with
BPA for 48 h without any medium change and then
washed and left to develop for another 48 h and being
examined at stage 45. Embryos were fixed in 4% paraf-
ormaldehyde and photographed under either a Leica
dissecting binocular microscope (upper panel) or Nikon
SMZ-U microscope. (Lower panel).
In situ hybridization immunohistochemistry and
photography
Whole-mount in situ hybridization of zebrafish embryos
was performed as described by [41]. Immunohistochem-
istry was performed as previously described [42] using
the acetylated tubulin primary antibody (Sigma). Stained
embryos were photographed with an AXIOIMAGER
microscope (zeiss) or an Olympus BX51 microscope.
Live embryos were photographed using Olympus SZX16
macroscope. Images were processed using the adobe
photoshop software.
Transient transfections
HeLa cells were maintained at 37°C in 5% CO2 in
DMEM-F12 (GIBCO), 5% foetal calf serum (FCS).
24 hours before transfection, cells were plated in 96-well
plates (20,000 per well) in DMEM-F12 (Invitrogen), 3%
Dextran-Coated Charcoal Serum (DCC) whithout red
phenol. Cells were transfected with Jet-PEI according
with the manufacturer’s instructions (Ozyme, Saint-
Quentin-en-Yvelines Cedex France). Per well, 25 ng of
the pSG5 expression vector for the ERa, ERb-A and
ERb-B, 100 ng of the estrogen-dependentluciferase
reporter construct (ERE-b-globin-Luc) and 50 ng of
CMV-b-galactosidase plasmid (pCMV-bGal)were trans-
fected. 48 hours after transfection, cells were harvested
in a lysis buffer [25 mM Tris-phosphate (pH 7,8), 2 mM
DTT, 2 mM EDTA, 10% glycerol and 1% Triton X-100]
and the luciferase activity was measured with the luci-
ferin solution [2 mM Tricine (pH 7.8), 1.07 mM
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(MgCO3) 4Mg(OH)2, 2.67 mM MgSO4, 0.2 mM EDTA,
0.53 mM ATP, 0.27 mM CoA and 0.48 mM luciferin]
on a luminometer. pCMV-bGal was used to normalize
the transfection efficiency.
Limited proteolysis assay
Assays were performed as described in [43]. Proteins
were synthesized in vitro using a TNT coupled Reticulo-
cyte Lysate System kit (Promega) and labeled with [35S]
methionine (Amersham Biosciences) according to the
manufacturer’s recommendations. BPA was incubated
with the protein at different concentrations (from 10
nM to 1 μM). After incubation at room temperature for
15 minutes with ligand, receptor proteins were digested
at room temperature for 10 minutes with trypsin. After
this incubation time, buffer was added and incubated
the mixture for 10 minutes at 100°C. SDS-PAGE was
performed using a 12% gel. Electrophoresis was carried
out using a BioRad gel apparatus at 170 V for 50 min-
utes and the polyacrylamide gel was visualized by
autoradiography.
In vivo luciferase assay
We used the transgenic ERE-Luc fish line described by
Legler et al. [44]. Male fish with a weight of 300 mg
(three to six months old) were exposed for 48 hours to
one ligand or to a mixture of two ligands in glass aqua-
ria (E2, ICI 182,780 and/or BPA). Ligands were dis-
solved in ethanol at concentrations of 10-1 M or 10-3 M
and titrated to final concentrations not exceeding a
solvent concentration of 0.01%. Single fish were anaes-
thetized (0.6 mM Tricain methanesulfonate) and trans-
ferred to an Eppendorf tube. Then, 135 mL of ice cold
Triton-lysis buffer (1% triton-X-100; 15 mM MgSO4; 4
mM EGTA pH 7.0; 35 mM glycylglycine pH 7.8; 1 mM
DTT) was added to each tube following homogenization
using a micropestle. After centrifugation the supernatant
was transferred to a new tube and extracts were mea-
sured in luminometric reporter gene assays carried out
in duplicates in a Microplate Luminometer (Anthos).
Light units from extracts of ligand-exposed fish and
from non-exposed fish were used to calculate fold
inductions.
Results
BPA exposure during early embryogenesis induces
abnormalities of the otoliths
Zebrafish embryos were treated from 5 hours post-fertili-
zation (hpf) onwards with concentrations of BPA ranging
from 0.01 μM to 100 μM. While exposure to BPA <5 μM
did not induced phenotypic abnormalities, treatment
with higher doses induced otolith malformations (Figure
1A). These effects were seen in a small proportion (<5%)
of embryos at 5 μM and increased at higher doses with
more than 50% of affected embryos at 25 μM BPA. Nota-
bly, 100 μM BPA induced embryonic mortality probably
linked to cardiac edema and cessation of blood flow.
Abnormalities included aggregation of the otoliths,
appearance of extra otoliths or their absence (Figure 1B).
The vast majority of embryos exhibit bilateral aggrega-
tion of both anterior and posterior otoliths (< 18 otoliths
forming an aggregate in the posterior otolith, Figure 1B).
In some cases, altered semi-circular canals development
was observed, but as this effect was highly variable it was
not further characterized. In addition we observed that
BPA had a mild effect on decreasing the general embryo
pigmentation (not shown).
Otoliths (otoconia in higher vertebrates) are composed
of calcium carbonate (CaCO3) and are required for nor-
mal balance and gravity sensing. Otolith formation
requires bringing together organic and inorganic com-
ponents in time and space. Disruption of any of these
processes can lead to the formation of missing, ectopic
or abnormally shaped otoliths [45]. Otolith defects in
BPA treated embryos have not been reported in earlier
studies monitoring BPA defects during vertebrate
embryogenesis [32,33,46]. The BPA-induced phenotype
is restricted to the otolith as the general shape of the
embryos is not affected even if in high dose treatments
we detect cardiac edema and stop of blood flow as pre-
viously observed [32] (Figure 1C). Moreover late BPA
exposure, after 24 hpf, does not alter anymore the devel-
opment of the otoliths (Figure 1C right panels).
In these types of studies, information on the bioavail-
ability, biotransformation and excretion of the tested
chemical are crucial to relate the waterborne exposure
levels to the actual internal dose reaching the biological
targets. Because limited data exist on the fate of bisphe-
nols in fish embryos, we determined the uptake and
metabolic profile of BPA and BPF (two bisphenols com-
mercially available as radio-chemicals) in zebrafish
embryos. To this end, 60 zebrafish embryos were incu-
bated in a volume of 50 mL of E3 1X medium in pre-
sence of 50 μM [14C]-BPA or 50 μM [3H]-BPF for
72 hours. Embryos and medium samples were collected
for radioactivity measurements and radio-HPLC analysis.
As shown in Figure 1D, the concentrations of bisphenols
measured in embryos at the end of the experiment cor-
responded to 0.7 μg BPA equivalent per mg fresh weight
and 0.22 μg BPF equivalent per mg fresh weight, respec-
tively. These values indicate that the concentration of
radiolabeled compounds was 27 and 11 fold higher in
embryos than in water, respectively. This result allowed
us to estimate that the levels of BPA and BPF accumu-
lating in the embryos were in the order of 10-3M and
5x10-4M, respectively.
Radio-HPLC profiles obtained from BPA exposed
embryos and from the water, exhibited a single
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radioactive peak, displaying the same retention time as
BPA itself (Additional file 1). In addition no metabolic
products were found in the water, suggesting that at this
late stage of development, zebrafish embryos were
unable to biotransform BPA. In contrast, BPF was
biotransformed by embryos, as shown by the radio-
chromatograms obtained for embryos extracts and E3
medium samples, respectively (Additional file 1). Due to
the low amount of available material, further investigations
on BPF metabolite structures could not be carried out.
We next examined whether BPA exposure had an
effect on otic vesicle development in another vertebrate
embryo. The Xenopus embryo was selected because, like
the zebrafish, effects on early development can be easily
followed in this transparent, free-living embryo. Xenopus
embryos were exposed to BPA during early development
(stages 18-40) for 48 hours and examined at stage 45.
Exposure to either 5 μM or 10 μM BPA caused a strong
dose-dependent reduction in the development of the
otoconia (i.e. Xenopus otoliths) (Figure 1D). We also
C
B D
E
Figure 1 BPA treatment induces otolith abnormalities. A: BPA induced otolith malformation is dose dependent. Embryos were treated with
different concentrations of BPA from 5 hpf onwards. Black bars represent embryos showing no otolith abnormalities, red bars represent treated
embryos showing otolith abnormalities. (*: P < 0.01, Fisher test after Bonferroni correction). B: Anterior otolith (ao, upper left) and posterior
otolith (po, upper middle) of control embryo and ao (lower left) and po (lower middle) of embryos treated with 70 μM BPA from 5 to 50 hpf
showing otolith aggregation. In some rare cases a single otolith (upper right) or extra otolith (eo lower right) are observed. C: Upper panel:
control embryo at 50 hpf (Upper right: close up of the otic vesicle). Lower panel: overall shape of BPA treated embryos form 6-50 hpf resembles
control embryos, but display otolith aggregates (arrow). Lower right: close up of the otic vesicle in a BPA treated embryo form 24-50 hpf
showing normal otoliths. D: After 75 hours of exposure, the concentration of BPA measured in embryos is 0.7 μg equivalent per mg fresh
weight and 0.22 μg of BPF equivalent per mg fresh weight; see also Figure 2 C-E. E: BPA induces malformation of the otic vesicle in Xenopus
embryos. Xenopus embryos were exposed to BPA (5 or 10 μM) from stage NF 18 to stage NF 40 (48 h) and examined at stage NF 45. The upper
panel shows the morphology of the otoliths (or otoconia [73]) in control and BPA treated embryos. Note that 5 and 10 μM of BPA induce a
progressive reduction in the size of the otoconia. The lower panel shows the semi-circular canals with a reduction in the distance between the
two semi circular canals (arrowheads) induced by BPA. Similarly, the morphology of the developing semi circular canals is flattened under BPA
treatment.
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observed a severe reduction of the semi-circular canals,
with the presumptive arch of the canals being flattened
by increasing doses of BPA (lower panel, Figure 1E).
BPA effect is time and compound-specific
To determine if the timing of BPA action corresponds
to that of inner ear organogenesis in zebrafish, two ser-
ies of experiments were done. First, BPA pulse treat-
ments of different lengths were started at 10 hpf and
continued until 18, 24, 30 or 38 hpf, a time frame cover-
ing the main steps of otic vesicle development that are
shown on Figure 2A [47]. The morphology of the oto-
liths was examined at 50 hpf. In all cases, exposure to
BPA (70 μM) during these critical periods induced oto-
lith malformation with 100% of the treated embryos dis-
playing otolith aggregates (Figure 2B, Upper red bars,
n = 30). Otolith aggregates were never observed in con-
trol embryos (n = 30). In a second series of experiments,
treatment started from 6 hpf onwards or at 2 h intervals
thereafter till 30 hpf (ie earliest treatment starting at
6 hpf and latest treatment starting at 30 hpf). Again, the
otolith morphology was examined at 50 hpf. When BPA
exposure began prior to or at 18 hpf, 100% of the
embryos displayed malformed otoliths (i.e. otolith aggre-
gates). When treatment began at 20 hpf the proportion
of affected embryos decreased to 85% (n = 40, Figure
2B, lower panel). However, almost no effects (only 2% of
the embryos affected, n = 40) were seen when treat-
ments began at 22 hpf (Figure 2B, lower panel). Treat-
ments starting after 22 hpf did not induce any otolith
defect (Figure 2B, lower panel and data not shown). Of
note is the fact that phenotype severity (i.e; number of
aggregates) is dependent on time of treatment onset.
The earlier the BPA exposure (i.e. the closer to mid-
blastula transition, 6 hpf), the stronger the phenotype
(See Additional file 2). According to Riley and collea-
gues [48] and Colantonio et al., [49], otic vesicle forma-
tion occurs at 18-18.5 hpf. Thus, our results suggest
that BPA acts prior to actual otolith formation per se,
potentially acting on determination of cells that will give
rise to the otoliths.
To test for the specificity of the observed phenotype,
we tested the effects of other bisphenols. Zebrafish
embryos were exposed to BPC, BPE or BPF. As BPA
weakly reduces pigmentation, the effects of each bisphe-
nol were recorded on otolith development and pigmen-
tation (Figure 2C). We observed differential effects of
each bisphenol on these endpoints with BPE producing
the most marked effects on both processes (Figure 2C,
D arrow). BPC was least disruptive, affecting neither
otolith nor pigmentation. Interestingly, we observed that
the presence of methyl groups on the central carbon
between the two phenols had no effect on the action of
the molecule on the otic vesicle (e.g. BPA, BPE and BPF
are active). In contrast, the presence of a dichloroethy-
lene group on the central carbon (e.g. BPC) abrogates
the disrupting effects of bisphenol (Figure 2E).
Taken together these results show that although the
phenotypic effects are observed only at high concentra-
tions, they disrupt a precise developmental pathway.
Indeed, the time dependency and the chemical specifi-
city suggest that this is not a general toxicity effect.
Developmental analysis of the BPA-induced otolith
phenotype
In order to gain insight into the developmental origin of
the phenotype, we compared the expression of several
markers of otic vesicle and otolith formation between
control and BPA-treated fish. First, we monitored if the
phenotype of BPA treatment was linked to a develop-
mental delay using a marker, pax2.a, that shows a nor-
mal pattern (revealing only a smaller otic vesicle at 18
hpf, data not shown).
Next, we checked whether the phenotype implicated a
defect in hindbrain patterning as this can occur when
specific pathways (e.g. FGF, RA) are disrupted [50,51].
The expression of egr2a, a marker of rhombomere 3
and 5 segmentation at 18 hpf was thus examined. egr2a
expression is not affected (Additional file 3A,B), suggest-
ing that hindbrain patterning in the region of the otic
vesicle is unaltered by the BPA treatment. We next
tested if the antero-posterior or the dorso-ventral pat-
terning of the otic vesicle was affected by BPA treat-
ment. Using atonal1 (atoh1a) and hmx3, two markers
expressed in the anterior part of the otic vesicle at 26
hpf, we showed that the antero-posterior patterning is
not affected in BPA treated embryos (Additional file
3C-F). Similarly, dorso-ventral patterning is not altered,
as displayed by dlx3b labelling at 26 hpf (Additional file
3G and 3H) [52]. Recently, Petko and colleagues [53]
identified otoconin 90 (oc90) as essential for normal oto-
lith development during zebrafish embryogenesis. When
translation of this gene was abolished, otoliths were
smaller in size, altered in shape or absent. To test for
possible links between the BPA-induced phenotype and
the oc90 phenotype, we studied oc90 expression in BPA
treated embryos at 24 hpf. In our hands, oc90 is
expressed in the ventral portion of the otic epithelium
(Figure 3A). In BPA-treated embryos a stronger signal
of oc90 expression is detected (Figure 3B). A similar up
-regulation of oc90 is observed in embryos treated with
another bis-phenol leading to otolith malformation, BPE
(Additional file 4). Therefore, we conclude that BPA
acts by altering directly or indirectly the expression of
genes implicated in otolith development. To better
understand the relationship between oc90 and BPA
action, we injected a published morpholino against the
oc90 gene [53]. The most dominant phenotype observed
Gibert et al. BMC Developmental Biology 2011, 11:4
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Figure 2 Bisphenol effects are time and compound specific. A: Live pictures of the developing otic vesicle from 18 to 50 hpf in zebrafish
embryo. B: BPA affects otolith in a restricted time window. Diagram showing the effect of 70 μM BPA treatments with different starting points
or length of exposure. Upper panel: BPA pulse treatments (red bars) were performed from 10 hpf. At different stage of development (18, 24, 30
and 38 hpf) embryos were washed and developed in BPA free medium (gray bars). Otic vesicles were scored at 50 hpf. Lower panel: BPA acts
prior 22 hpf to induce otolith defects. Treatments started prior or at 18 hpf lead to 100% of otolith defects. Treatment started from 20 hpf
onwards lead to 85% of embryos with otolith defect. Treatment started at 22 hpf lead to only 2% of affected embryos. Treatments started later
did not lead to any otolith defect. Red bars represent time when embryos were exposed to BPA. Gray bars represent time when embryos were
not exposed to this compound. C: Various bisphenols affect otolith development and/or pigmentation. Embryos were treated from 5 to 72 hpf
and malformed otolith or pigmentation defects scored (+++ indicates maximum defect, i.e. malformed otolith or total lack of pigment).
Treatment of embryos with either BPA (70 μM) or BPE (70 μM) resulted in malformed otoliths. BPE also affected pigmentation, as did BPF (50
μM). BPC (70 μM) was without clear effects in these assays. D: Pictures of the effect of BPC, BPE and BPF on otolith development. All embryos
were exposed to 70 μM of bisphenol. Note that only BPE gives an otolith phenotype similar to what in observed in BPA treated embryos with
otolith aggregates marked by a black arrow. E: Chemical structures of BPA, BPC, BPE and BPF.
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is a single posterior otolith (Additional file 5C) with
sometimes the presence of 2 or 3 small otoliths in con-
tact with each other. This finding recalls those of Petko
and colleagues [53]. However, when we treated these
oc90 morphants with BPA we observed a full BPA phe-
notype (i.e. high numbers of otholith aggregates) in the
posterior developing otolith (Figure 5D). Therefore, even
in the absence of oc90, BPA exposure can lead to otolith
aggregation in a similar fashion to control treated
embryos (see Additional file 5B and 5D).
We then studied if and how the inner structures of the ear
were affected by BPA treatment at later embryonic stages
(50 hpf). To this end we analyzed the expression of ugdh
[54,55], aldh1a3 [56] and bmp4 [56]. ugdh is expressed in
specific regions of the otic vesicle (anterior and posterior
cristae and endolymphatic duct and cranial epithelial pro-
jection [54]. In BPA treated embryos ugdh expression is
severely reduced especially in cranial epithelial projec-
tions, endolymphatic duct and in the posterior cristae
(Figure 3E and F) while expression persists in the anterior
cristae. Similarly, aldh1a3 expression is decreased in
endolymphatic duct and posterior cristae while still
expressed in anterior cristae, the cranial epithelial projec-
tion and the anterior macula (Figure 3C and 3D). In con-
trast, bmp4 expression in the anterior lateral and
posterior cristae is unaffected (Figure 3G-H). The otic
vesicle is highly ciliated and the cilia are important for
otolith formation. We thus decided to look at these cilia
in BPA treated embryos, but did not detect any difference
in number, shape nor size of the cilia of the macula in
control embryos and BPA treated embryos (Figure 3I,J).
This result correlates well with our in situ results as all
markers of the anterior macula are expressed normally in
BPA treated embryos (Figure 3D,H).
Taken together these data reveal that BPA has a broad
effect on the specification of several inner ear territories.
The morphological otolith phenotype is therefore only
one aspect of the more general action of BPA in this
organ (see Discussion).
BPA effects on otolith development are estrogen-
independent
BPA is known to act as a partial agonist of estrogen (E2)
receptors (ERs) in mammalian systems [20-24]. In addi-
tion several recent observations suggest that both in
mammals and fish estrogen signalling plays a role in
hearing suggesting a possible connection with otic vesi-
cle formation [57,58]. We questioned whether BPA is
able to bind to the three zebrafish ERs (esr) and regulate
transcription in transient transfection assays. A limited
proteolysis assay was carried out using the three pre-
viously cloned receptors, esr1, esr2a and esr2b [59,60] of
which esr1 and esr2a are ubiquitously expressed during
zebrafish embryogenesis including in the otic vesicle
[61]. As seen in Additional file 6, each of the three ERs
is protected against trypsin degradation in a dose-depen-
dent manner with both E2 and BPA. However, the affi-
nity for E2 is three orders of magnitude greater with
protection occurring at all E2 concentrations above 0.01
μM, whereas 1 μM to 10 μM BPA is required to protect
from trypsin digestions. We thus conclude that BPA can
bind all three ERs, albeit at low affinity.
Figure 3 Expression of markers of inner ear development in zebrafish embryos are affected by BPA treatment. (A,B)oc90 a gene require
for otolith formation in zebrafish is up-regulated under BPA treatment at 24 hpf (n=30). In situ for control and BPA treated embryos were
performed in the same tube with the tip of the tail removed for the control embryos. (C,D)aldh1a3 is detected in the anterior cristae (ac), the
cranial epithelial projection (cp), the endolymphatic duct (ed), the posterior cristae (pc) and the anterior macula (am) in wild type zebrafish
embryo at 50 hpf (M), its expression is reduced in ac, cp and am and is absent in ed and pc in BPA treated embryos from 6 hpf onward (D).
(E,F) Expression of ugdh at 50 hpf in control otic vesicle (E) is detected in the ac, cp, ed and pc. In BPA treated embryos from 6 hpf onwards
(D), ugdh expression is severely reduced and remains solely detected in the ac and the cp. (G,H) Expression of bmp4 in control embryos at at 50
hpf (G) in the anterior (ac) lateral (lc) in the posterior cristae (pc) and the endolymphatic duct (ed) remains unaffected after BPA treatment (H).
(I,J) Confocal microscopy of acetulated tubulin antibody staining showing the presence of the ciliated macula (white arrow) in control embryos
(I) and in BPA treated embryos (white arrow in J).
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The next question was whether ERs could be activated
by BPA. Transient transfections were done using HeLa
cells, which do not express endogenous ERs. These cells
were co-transfected with a luciferase reporter gene
under the control of consensus estrogen response ele-
ment (ERE) along with an expression vector encoding
one or the other of the ERs: Era, Erb-A and Erb-B.
Cells were exposed to either increasing concentrations
of E2 or BPA (Additional file 6). We found that lucifer-
ase expression was induced in the presence of E2 and
BPA, but that the ED50 for E2 was around 1 nM or
0.01 μM dependent on which of the ER was used,
whereas the ED50 for BPA on each ER was 100 to 1000
times higher (1 μM) This result corroborates the results
of the limited proteolysis assay described previously.
Thus BPA binds and activates the three zebrafish ERs in
the micromolar range.
To verify that BPA elicits a transcriptional response
in vivo we used a transgenic reporter zebrafish line that
contains a luciferase gene under the control of an ERE
linked to a minimal promoter (3xERE-TATA-Luc) [44].
We performed this assay in juvenile fish (3 months old)
since, in our hands, E2 did not induce a detectable luci-
ferase response using these transgenic fish during
embryonic stages [62]. The transgenic ERE-Luc fish
were treated with BPA at 10 μM. The Luc activity was
then measured from pooled pairs of juveniles. In pre-
sence of 1 μM E2, we observed a 620 fold induction of
Luc activity, whereas, as expected, ICI 182,780 (ICI),
does not induce any activation and completely abolishes
E2 induced activity. In presence of 10 μM BPA, Luc
activity is weakly induced (<7 fold), but no induction is
detected when co-treated with 1 μM of ICI, clearly sug-
gesting that this effect is ER-dependent. These results
show that BPA can weakly activate the estrogen pathway
in vivo.
We next examined if the otolith phenotype was linked
to an alteration of the estrogen signalling pathway.
A first approach was to test whether the ER agonist, E2,
or the ER antagonist, ICI, modified BPA effects on otolith
morphology (Figure 4). Zebrafish embryos were exposed
to BPA with or without either 1 μM E2 or 1 μM ICI. As
shown in Figure 4A and B, neither ICI nor E2 treatment
alone induced phenotypic alteration of the otoliths (0%,
n=120). However, whereas E2 had absolutely no effect on
BPA-induced phenotype in terms of morphology or fre-
quency, ICI exhibited a certain level of synergy with BPA,
since there were consistently more affected embryos after
co-treatment than with BPA alone (Figure 4A; 56.7%,
n = 120 of otoliths affected upon BPA exposure 5.10-6 M
alone versus 73.3%, n = 120 of otoliths affected upon
BPA exposure 5.10-6 M supplemented with ICI 10-6 M).
However, in this case the severity of the morphological
phenotype was unaltered. Taken together, these results
indicate that the BPA action on otic vesicle development
is not mediated primarily by ERs but that, to some
extent, modulation of ERs may alter the frequency of the
BPA-induced effect.
The BPA-induced otolith phenotype is TR-independent
BPA has been shown to be a TR antagonist in mamma-
lian cells [28,30] and TR knock-out mice have a hearing
defect linked to abnormalities of ear development
[63,64]. More recently in vivo work demonstrated that
BPA inhibits T3 signalling in Xenopus embryos [31] and
prevents metamorphosis in Xenopus tadpoles [35]. As
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Figure 4 BPA effect on otolith development is estrogen
receptor-independent. Morphology of the inner ear of zebrafish
embryos at 48 hpf following exposure to BPA with or without ER
antagonists (ICI 182 780) or agonists (17-b estradiol, E2). Treatment
with either 1 μM ICI (A) or 1 μM 17-b estradiol (B) from 5 to 48 hpf
does not induce any malformation of the developing semi-circular
canals nor otoliths. Moreover, the BPA-induced otolith phenotype is
not rescued when embryos are co-treated with BPA 5 μM +ICI 1 μM
(A) or BPA 5 μM +bE2 1 μM (B). Interestingly, co-treatment with BPA
5 μM +ICI 1 μM lead to in increased ratio of affected otolith than a
treatment with BPA 5 μM alone (A). On the other hand co-
treatment with BPA 5 μM +bE2 1 μM gives a similar ratio than a
treatment with BPA 5 μM alone (B).
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for the ZfERs, we tested if ZfTRs could be activated or
inhibited by BPA. These data show that BPA was inac-
tive on ZfTRaA being unable to induce the activation of
the receptor or to inhibit its activity in presence of low
amount of T3 (data not shown).
To test the effect of BPA on the TH signaling path-
way, we used a pharmacological approach to assess
whether BPA action on zebrafish otolith implicated TH
signalling. We first observed that treatment with high
doses of T3 (1 μM) did not induce any obvious morpho-
logical abnormalities of the otoliths (Figure 5B). In order
to prevent the rapid degradation of exogenous T3 by
endogenous deiodinases, the experiment was repeated in
the presence of two compounds that inhibit deiodinase
activity, either iodopropanoic acid (IOP) or PTU [65].
Similar results were obtained with or without these
agents. Treatment of 40 embryos with BPA 70 μM
alone or BPA + T3 gave similar phenotypes (compare
Figure 5C and 5F) and frequencies (data not shown). To
carry out a more sensitive assessment of potential inter-
actions between the two pathways, embryos were treated
with suboptimal doses of BPA (35 μM, i.e. half the pre-
vious dose) and monitored to see if 1 μM T3 acted
synergistically with BPA on the otolith phenotype. As
found previously, co-treatment with T3 had no effect
(compare Figure 5D and 5E). These data suggest that
there are no interactions, neither positive nor negative
between BPA target(s) and TH signalling.
BPA and ouabain-induced otolith formation
One of the main enzymes involved in ion exchange and
various aspects of inner ear formation are the ouabain
sensitive Na+/K+ ATPases [54,66]. Addition of ouabain
to embryos was used to examine whether the effects of
BPA implicated Na+/K+ ATPases. Ouabain exposure
(1.8 mM from 6 hpf onwards) caused aberrant develop-
ment of otoliths, with either complete absence (20% of
the embryos) or one misformed otolith (80%; see Figure
6B). Higher doses led to embryonic mortality at 48 hpf
as reported by Blasiole et al. [54]. This phenotype could
be viewed as opposite to that caused by BPA (at 70 μM
from 6 hpf onwards) i.e. formation of multiple small
A B C
D E F
Ctrl T3 BPA Full
BPA 1/2 BPA 1/2+T3 BPA Full+T3
Figure 5 BPA effect on otolith development is thyroid hormones independent. (A) Control otic vesicle at 50 hpf with two otoliths. (B)
Treatment with 1 μM of T3, from 5 hpf onwards lead to a normal otolith development. (C) 70 μM BPA treated embryo from 5 hpf onwards lead
to otolith aggregates. (D) Half dose of BPA, 35 μM, does not affect otolith development. (E) Co-treatment of half dose of BPA, 35 μM,
supplemented with 1 μM of T3 does not affect otolith development. (F) Co-treatment of full dose of BPA, 70 μM supplemented with 1 μM of T3
lead to a similar otolith phenotype than BPA 70 μM alone (compare C with F).
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aggregated otoliths (Figure 6C). Interestingly when we
co-treated embryos with 1.8 mM ouabain + 70 μM BPA
a normal otolith formation was observed (Figure 6D):
two otoliths are present in these fish. We interpret this
as a rescue of the BPA effect by ouabain treatment. This
suggests that the two compounds have opposite effects:
on the one hand, BPA promotes multiplication and
aggregation of otoliths, whereas, inversely, ouabain
blocks their formation. We thus explored the dose-
dependency of this effect. Using a lower dose of ouabain
(0.9 mM, half dose) induced only very limited rescue of
the full dose BPA phenotype. However, with this half
dose ouabain and full dose BPA embryos were less
severely affected than the full dose BPA alone (Compare
Figures 6C and 6E). In contrast, full dose ouabain plus
lower dose BPA (50 μM) treated embryos also displayed
normal otoliths, with two distinct otoliths while only
one misshapen otolith resulted from full dose ouabain
alone (Compare Figures 6F and 6B).
It has been recently reported that the morpholino
knock-down of one subunit of Na+/K+ ATPase a 1a.1
(a 1a.1) phenocopies the ouabain inhibition of otolith
formation [54]. We thus tested if a 1a.1 was required
for the occurrence of the BPA phenotype. We observed
the same phenotype as Blasiole et al. [54] after a 1a.1
morpholino injection, i.e. a complete loss of otolith
(Figure 6G). Treatment with 70 μM BPA of a 1a.1 mor-
phants (n = 20) gives rise to the same phenotype as a
1a.1 morphants alone: the complete loss of otolith
(Figure 6H). When a lower dose of morpholino is used,
a single small otolith is observed (Additional file 7C).
When morpholino treated embryos are treated with 70
μM of BPA, extra otoliths (2-3 only) are observed
(Additional file 7D). However high level of otolith aggre-
gates are never observed (compare Additional file 7B,D).
This result suggests that a lower level of Na+/K+
ATPase alpha 1 can reduce the BPA-induced effect on
the otolith, though this relationship needs further analy-
sis (see Discussion).
One possibility to explain these results would be that
BPA induces expression of a1a.1. We therefore tested if
BPA treatment modulates a1a.1 expression at 24 hpf
(Figure 6I and 6J). We found that it is not the case:
a1a.1 is detected both in terms of localization and
intensity in a similar way in control and in BPA treated
embryos. Blasiole et al., [66] showed that three other Na
+/K+ ATPases are expressed in the developing ear. We
carried out in situ hybridization with probes for these
three other Na+/K+ ATPase enzymes in BPA treated
embryos. No effect on their expression was found com-
pared to control embryos (data not shown). These data
allow us to exclude the possibility that Na+/K+ ATPase
genes are regulated at the transcriptional level by BPA.
However, it remains possible that BPA interferes with
Na+/K+ ATPase function in other indirect ways, e.g. by
inhibiting its enzymatic activity, by interfering with the
stability of the protein and/or its post-translational mod-
ifications or affecting sub-cellular distribution.
Discussion
BPA affects otolith development
Despite the fact that the effects of BPA on development
have been the subject of numerous investigations, few
experiments have explored effects during embryogenesis
[18,19,36]. Here, the distinct advantages of the aquatic,
free-living embryos used in this study come to the fore,
?1a1 MO
?1a1 MO+BPA
?1a1
Ctrl
BPA
Figure 6 Chemical inhibition of Na/K ATPase rescues the BPA induced phenotype. (A) 50 hpf control embryo with two normal otolith.
(B) Treatment with 1.8 mM ouabain from 6 hpf onwards leads to one misformed otolith. (C) Embryo treated with 70 μM BPA from 5 hpf onwards
leads to otolith aggregates. (D) Co treatment with 70 μM BPA and 1.8 mM oubain from 6 hpf onwards leads to normal otolith. (E) Co treatment
with 70 μM BPA and 0.9 mM oubain from 6 hpf onwards leads to a mild BPA like phenotype. In some cases one almost normal otolith is found
(arrow). (F) Co treatment with 50 μM BPA and 1.8 mM oubain from 6 hpf onwards leads to two normal otoliths. (G)a1a1 morphants display a
complete absence of otolith. (H) 70 μM BPA of a1a1 morphants did not rescue otolith formation and result in a complete absence of otolith.
(I)a1a1 is expressed in the lower membrane of the otic vesicle at 24 hpf. (J) A similar expression of a1a1 is detected in BPA treated embryos.
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notably their external and maternally-independent
development, and their transparency that together facili-
tate investigation of morphological phenotypes. Indeed,
the main result from our study is that BPA specifically
affects otolith development during zebrafish and Xeno-
pus development. The otolith phenotype that we
observed is not linked to the cardiac effect previously
observed since the timing of the two events differ, the
otolith phenotype being dependent on treatments car-
ried out during earlier developmental periods. Our data
show that BPA acts early in development, during zebra-
fish embryogenesis, before 20 hpf to affect otolith for-
mation and that this effect is specific to BPA and closely
related bisphenols, since another molecule of the same
class (e.g. BPC) does not have the same effect. This
observation underscores the possible relevance of the
phenotype we describe.
It is interesting to note that the timing of BPA exposure
resulting in otolith phenotype actually corresponded to
the timing of otic vesicle organogenesis. The otic placode
becomes visible at approximately 16 hpf and forms a vesi-
cle with a lumen by cavitation at approximately 18 hpf
[67] (see Figure 2A). Two otoliths appear in the lumen by
19.5 hpf, and at about 24 hpf, the first sensory hair cells
are seen, grouped in two small patches, one beneath each
otolith, corresponding to the future macula. We found
that BPA affects inner ear development in a precise win-
dow, at the time of the first sign of morphological appear-
ance of the otoliths, that is at 20 hpf. Indeed, if BPA
treatment was delayed till just 22 or 24 hpf, no effects on
otolith formation were found. This precise timing of BPA
action is indicative of an interaction with specific targets
active during early otolith development. These observa-
tions emphasize that the effects are not due to acute toxi-
city but are due to a specific interference with a
developmental process. The fact that other bisphenols are
inactive also suggests that BPA interacts with a precise
selectivity on specific targets. In addition no sign of acute
cellular stress such as apoptotic cells or necrotic patches
were detected in the embryos after BPA exposure (data
not shown).
It is important to note that BPA induces abnormalities
of otolith development in two distant vertebrate species,
zebrafish and Xenopus. Interestingly, the two phenotypes
are different. In zebrafish we observed aggregates of oto-
liths with sometimes loss of one of the otolith. In con-
trast, in Xenopus BPA induces a strong dose-dependent
reduction in the development of otoliths and a severe
reduction of the semi-circular canals. In zebrafish we
sometimes observed abnormalities of semicircular canals
but with variable penetrance. We consider that this late
phenotype may be a consequence of an early defect. In
Xenopus, BPA was recently shown to induce malforma-
tions of the head region [36]. In this study, treatment
with 25 or 50 μM of BPA resulted in scoliosis and mal-
formation of the head region including a shortened dis-
tance between the eyes. Here, we observed a similar
phenotype when BPA treatment was begun at the egg
stage at these concentrations.
Our experiments reveal that only some bisphenols
affect otolith development. BPA, BPE and to a lesser
extent BPF induced otolith phenotypes whereas BPC
was inactive. These differences could be attributed at
least in part to dissimilarities in terms of bioavailability
and metabolism of bisphenols in embryos, resulting in
variations in concentrations of these bisphenols in tar-
get tissues. Comparing the fate of BPA and BPF, the
bio-concentration and biotransformation of these com-
pounds differed substantially. Residual levels of BPA in
embryos were 2.5 fold higher than calculated for BPF.
Furthermore, in the case of BPA no break-down pro-
ducts were found, as most of BPF was fully metabo-
lized by the end of the experiment. Due to
methodological limitations, these metabolic analyses
could not be extended to other bisphenols. However,
the data indicate that the extent of the phenotypic
effects may be related to the uptake, biotransformation
and elimination of these chemicals by zebrafish
embryos. Perez et al. [14], using MCF7 human breast
cancer cells in culture, demonstrated that the estro-
genicity of bisphenols was influenced not only by the
length of the substituents at the bridging carbon, but
also by their nature. In a yeast two-hybrid assay, Chen
et al. [13] ranked the estrogenicity of bisphenols as fol-
lows: BPB > BPP > BPA > BPE > BPF > BPS. Interest-
ingly we found that some of these compounds also act
to reduce pigmentation and that the pharmacology of
this effect is clearly different: for pigmentation BPE
and BPF are clearly the most active compounds, fol-
lowed by BPC and BPA that show modest effects.
These data suggest that bisphenols interfere with dif-
ferent targets in the otoliths and in the pigmentation
developmental pathways.
The lowest concentration at which an effect was
observed was 5 μM, but with low penetrance (less than
5% affected embryos). At 25 μM the majority of the
embryos were affected and all at 70 μM. The lowest
active concentration (5 μM) corresponds to more than
1 mg/mL several orders of magnitude higher than the
levels reported in aquatic environments [4-6] or in
human serum [8,9]. Of note however is the fact that the
concentration of BPA found in amniotic fluid was
approximately five-fold higher than levels measured in
maternal plasma [10]. Even these high concentrations
however are markedly lower than the one needed in our
assay to generate a phenotype. Thus, the effect we
observe in the aquatic species is probably not relevant
to human populations.
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A previously undescribed otolith aggregate phenotype
The development of the inner ear in fish and amphi-
bians is representative of the development of inner ears
of vertebrates in general. Vertebrate inner ear develop-
ment is a self-contained model system for fundamental
research into genetic control of development and, as
shown here, for detecting the effects of potential EDCs
on early vertebrate development. Whitfield et al. [47]
carried out a large scale screen of zebrafish mutants
induced by N-ethyl-N-nitrosurea treatment. Mutations
occurring in no less than 58 genes leading to defects in
the development of either the semicircular canals and/or
the otoliths were identified [47]. In this screen the
authors did not examine fine morphology of the inner
ear, such as hair cells, and so they estimate that many
more genes are potentially involved in the process.
Interestingly, BPA induces a new zebrafish otolith
phenotype. Most of the phenotypes of otolith formation
are caused by the specific knock-down or mutation of a
given gene [47,68]. Many of them result in a small mal-
formed ear, a defect in the AP or DV axis, or in specific
deletion of specific structures (semicircular canals, oto-
liths) but to our knowledge the phenotype we describe
here has not been previously described. The abnormal-
ities we observe included aggregation of up to 18 oto-
liths (Figure 1B, lower panel), appearance of multiple
otoliths or their absence (Figure 1B). It is clear that the
majority of the embryos exhibit a bilateral aggregation
of both the anterior and posterior otoliths. This is
clearly different (or opposite to) to the loss of otolith
observed by Blasiole et al. [54] after treatment with oua-
bain or morpholino knock-down of the Na+/K+ ATPase
a1a.1. In fact the phenotype that we find most similar
to the effect of BPA is the one seen after inhibition of
the oc90 gene, a member of PLA2-like otoconin family
[53]. It is interesting to note that oc90 is clearly upregu-
lated in the otic vesicle after BPA treatment suggesting
it may be play an important role in generating the BPA
phenotype. Nevertheless we still observed the otolith
aggregation induced by BPA following oc90 knock-
down, suggesting that this gene is not required for BPA
action. Given the fact that BPA up-regulates oc90
expression we cannot exclude that oc90 act as a modi-
fier of BPA action but this remains to be addressed
experimentally.
The developmental basis of the phenotype was ana-
lyzed by studying the expression of gene markers. We
found that the patterning of the otic vesicle placode and
the hindbrain segmentation are normal and that the
antero-posterior and dorso-ventral axes of the otic vesi-
cle are correctly patterned. Thus, despite the fact that
BPA acts prior to 20 hpf we only detect defects with
gene markers at later stages, suggesting these modified
expressions derive from early action of BPA on an
unknown target. The change of gene markers observed
suggests that the phenotype extends much further than
a simple abnormality in otolith formation. Indeed, with
aldh1a3 and/or ugdh we observed a loss of expression
in specific regions such as cranial epithelial projections,
endolymphatic duct and in the posterior cristae. This
result is in accordance with the fact that we often see,
with a variable penetrance, morphological alterations of
the semicircular canals. Of note are the changes of
expression observed in otic vesicle markers after BPA
treatment, which are reminiscent of the changes
reported by Petko et al., [53] after oc90 inhibition, with
a normal msxC and dlx3b expression in both cases. The
early timing of the effects in our data suggest that BPA
exposure can have multiple consequences for the late
development of the ear, resulting in abnormal formation
of the otolith as well as other defects such as in the
semicircular canals. Unfortunately, results from the in
situ analysis do not really clarify the causes of the dra-
matic phenotype in otolith aggregates. Up-regulation of
oc90 might be a determinant factor for this phenotype.
In fish, otoliths are composed of calcium carbonate crys-
tals condensed on a core protein matrix. oc90, is the
ortholog of the mammalian otoconin-90 gene which
encodes the major matrix protein of otoconia. Therefore
it is tempting to speculate the with an excess of signal
that will lead to the development of the otolith the con-
sequences will be an excess of otolith as observed in our
BPA treated embryos. The precise mechanisms underly-
ing this effect have yet to be understood.
Interaction with nuclear receptor pathways
Much data in the literature show that BPA interferes
with the estrogen signalling pathway through direct
binding to ERa or ERb and thereby induce an ER ago-
nist or SERM (Selective Estrogen Receptor Modulator)
[19]. We have indeed verified that BPA binds to and
positively regulates the activity of the three ERs present
in zebrafish, although at higher concentration (ED50 at
the micromolar range) than in mammals [22].
Estrogen receptor signalling is intricately implicated in
the development, function and regeneration of the inner
ear [69]. It was therefore a reasonable working hypoth-
esis that the effects of BPA implicated interference with
ER signalling during otic vesicle development. We tested
this hypothesis in three ways. First, we examined the
effects of estrogen agonist and antagonist activity on
otolith development either alone or in combination with
effective doses of BPA. We observed only a weak
increase of the cotreatment of BPA and ICI on the
number of affected fish (see below). Secondly, we stu-
died if BPA in zebrafish could activate an ERE-Luc
transgenic reporter gene [44]. We found a modest effect
at the concentrations that clearly induce the phenotype
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(10 μM). These data thus suggest that BPA does not act
in an estrogen receptor-dependent manner during oto-
lith development. Several recent observations in the lit-
erature indeed suggest that BPA have a much broader
set of targets than previously expected. For example,
recently the genes responding in male zebrafish liver to
the exposure to 17 b-estradiol, and BPA were identified
through a microarray analysis [70]. Interestingly these
data reveal that the transcriptional network regulated by
17 b-estradiol and BPA in zebrafish are very different.
These observations are fully consistent with estrogen
receptor-independent effects of BPA that we describe
here through developmental analysis. The fact that we
observed a synergy when we treated the fish with BPA
and with the anti-estrogen ICI suggests a possible con-
nection of the BPA targets and estrogen signalling. This
idea is consistent with several recent observations sug-
gest that both in mammals and fish the estrogen signal-
ling play a role in hearing, suggesting a possible
connection with otic vesicle formation [57,58]. The
molecular and developmental basis of this cross-talk
remains to be explored.
Several data have recently suggested that both TR
isoforms (TRa and TRb) can be targets of BPA
(reviewed in [28]). In transient transfection experi-
ments, BPA (in the micromolar range) suppressed T3-
stimulated transcriptional activity stimulated in a dose
dependent manner. Since T3 and TRb are important
for ear development [63,64] we thus tested if the
action of BPA in zebrafish otolith development could
be linked to its interference with the TR signalling sys-
tem. We observed no obvious interaction between
BPA, T3 and otolith formation: the addition of 1 μM
T3 did not interfere, either positively or negatively,
with the phenotype induced by BPA. BPA was tested
at an optimal (70 μM) or a suboptimal (35 μM) dose
of BPA and in none of these situations did we observe
an effect of added T3. Thus, interference with the TH
signaling pathway does not seem to be responsible for
the BPA-induced phenotype. However, induction of
deactivating deiodinases by the exogenous T3 cannot
be excluded, a phenomenon that would neutralize the
exogenous T3. The lack of BPA interaction with TH sig-
nalling is in accordance with our previous observation
that altered expression patterns of TRs during otic vesi-
cle development in zebrafish could not be detected [61].
The BPA-induced phenotype and Na+/K+ ATPase activity
Na+/K+ ATPase are key enzymes implicated in cell
homeostasis by the maintenance of electrochemical gra-
dients. Na+/K+ ATPase activity has been implicated in
otic vesicle formation and otolith development shown by
treatment with a chemical inhibitor and morpholinos
that inhibit a subunit of this enzyme [54,66]. The Na+/K+
ATPase enzyme is composed of functionally distinct sub-
units each with multiple isoforms encoded by different
genes [54]. In the case of inner ear development, inhibi-
tion of Na+/K+ ATPase subunits interferes with otolith
and semicircular canal biogenesis, though the mechan-
isms implicated are still unclear [54]. Numerous cell
types are implicated in the formation of otoliths [71]. In
fish, otoliths are secreted into the otocyst (the part of the
inner ear containing the otoliths) then captured by cilia
of specialised cells that tether the anterior and posterior
otoliths in place at each pole of the otocyst. The first
crystals tethered serve as seeds for further growth. Na+/K
+ ATPase could be required for determining electroche-
mical gradients during various parts of these processes.
In the growth of the semicircular canals, Na+/K+ ATPase
subunits are expressed in the areas that give rise to the
protrusions that determine their growth.
In our experiments both BPA and ouabain, the inhibi-
tor of Na+/K+ ATPase, induced opposite phenotypes
and combination of lower doses of each chemical res-
cued otolith formation. This result could indicate that
the effects of BPA are dependent on an Na+/K+ ATPase
activity and one of the heterodimeric enzymes expressed
in ear. To test this hypothesis knock-down of a1a.1, the
major Na+/K+ ATPase subunit expressed in the otic
vesicle was carried out and showed that, indeed, the
BPA phenotype cannot be observed without this
enzyme. Nevertheless this effect is difficult to interpret
since it may be simply be linked to the inability of
a1a.1-morphants embryo to form otoliths properly.
Combined with the pharmacological interaction noted
above (BPA rescues the effect of ouabain; Figure 6),
a possible scenario is that a1a.1, and more generally
Na+/K+ ATPase activity act downstream of BPA target
genes in the otic vesicle. However, this is not the case as
we saw no effects of BPA exposure on the expression of
a1a.1 or on other Na+/K+ ATPase subunits (Figure 6
and data not shown). It is also possible that the two
pathways are independent. If a1a.1 is strictly required
for otolith formation, the morphogenesis defects
induced by BPA cannot be observed in the absence of
otolith. By injecting a sub-optimal dose of a1a.1 the sig-
nalling cascade dependent on a1a.1 can be activated
causing a small otolith to form. Once formation is
initiated, this otolith treated with BPA will still form an
aggregate but due do a low level of a1a.1protein present
in the embryo, due to morpholino injection, the aggre-
gate phenotype is mild compared to wild type. This sce-
nario implies that the effect of BPA on Na+/K+ ATPase
and otolith formation is indirect. However, if this were
the case one would not see a rescuing effect of BPA and
ouabain combination that we observed. Taken together,
these results suggest a link between BPA and Na+/K+
ATPase during induction of otolith malformation, but
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the precise molecular nature of this link and the exact
degree of this dependency remains to be explored.
Conclusion
In this manuscript we show that BPA affects otolith
development in two vertebrate species, zebrafish and
Xenopus. In both cases the deleterious effects are limited
to a time window corresponding to the period of otic
vesicle development. Moreover, neither estrogen nor
estrogen antagonists, nor TH modify the BPA response,
underscoring the concept that the effects observed are
estrogen and TH-independent. We conclude that verte-
brate organogenesis can be modified by BPA through
novel mechanisms. A clear link with the Na+/K+ ATPase
system was observed. Our experiments provide an
example of a developmentally relevant defect generated
by BPA treatment that is independent of its main mode
of action which is interaction with the estrogenic or TH
signalling pathways. These results suggests that the clas-
sical way of studying endocrine disruptors, that is by
defining precise “end points” based on classical risk
assessment data can some time be misleading because
the focus on a specific type of defect [62,72]. In these
cases, phenotypes based on unknown mode of action of
the molecule will be overlooked. We believe that zebra-
fish and Xenopus, that allow medium-throughput
screening of EDCs, will be powerful systems to test the
effects of these compounds in an unbiased manner.
Additional material
Additional file 1: Metabolic profile of BPA and BPF. (A) Typical radio-
HPLC metabolic profile obtained following incubation of radio-labeled
BPA (70 μM [14C]-BPA) in a volume of 25 ml of E3 1X medium in the
presence of 10 zebrafish embryos for 72h. Only a peak of BPA and
unexcretable metabolic products are found in the water. It is noteworthy
that 99.8% of the radioactivity is found in the water 24h later, indicating
that only 0.2% of the BPA in the aquarium water is taken up by the
embryos. (B) Typical HPLC profile of radiochemicals present in zebrafish
embryos (left) and in E3 medium (right), exposed to 3H-BPF (5.10-5M).
Analyses were performed on samples collected at the end of the
experiment (72h exposure).
Additional file 2: Early BPA treatment leads to a full BPA phenotype
at 50 hpf. (A) Control untreated embryos. (B) BPA treatment from 6-10
hpf or (C) 10-15 hpf lead to a full penetrence of the otolith aggregate
induced phenotype. All embryos were photographed at 50 hpf.
Additional file 3: Expression of markers of inner ear development
in zebrafish embryos that are not affected by BPA treatment. (A,B)
egr2a expression at 18 hpf is unaffected under BPA treatment. (C-F)
Expression of anterior markers of the otic vesicle (arrows), athonal1
(atoh1a) and hmx3 at 26 hpf, are not affected by BPA exposure. (G,H)
Expression of a dorsal marker of the otic vesicle, dlx3b at 26 hpf, remains
unaffected by BPA treatment. (I,J) Expression of msxC at 50 hpf in the
anterior (ac) lateral (lc) and posterior cristae (pc) remains unaffected after
BPA treatment.
Additional file 4: oc90 expression in the otic vesicle is up-regulated
after BPE treatment. (A) Control embryo showing normal expression of
oc90 in the otic vesicle at 24 hpf. (B) BPE treated embryo treated from 6
hpf onwards, fixed at 24 hpf showing up-regulation of oc90 in the otic
vesicle).
Additional file 5: Loss of oc90 does not abolish the BPA induced
phenotype. (A) Control otolith. (B) BPA treated embryos form 6 hpf
onwards showing otolith aggregates, (black arrow) in both otoliths. (C)
oc90 morpholino injected embryo with an absent anterior otolith. (D)
oc90 morpholino injected embryo treated with BPA form 6 hpf onwards
showing an aggregate of otolith (black arrow) in the only developing
otolith. All embryos were observed at 50 hpf.
Additional file 6: BPA is a weak agonist for the three zebrafish ERs.
(A) Limited proteolysis assays of in vitro translated zebrafish Era, Erb-A
and Erb-B with E2 as ligand (right hand blots, arrows) and BPA as ligand
(left hand blots, arrows). For each proteolysis panel, the first lane
represents the undigested protein, lane 2 shows digestion of the
receptor in the absence of ligand, lanes 3 to 8 show increased digestion
of the receptor in the presence of 10 fold decreasing concentrations of
E2 and BPA from 10-3M to 10-8 M. (B) BPA weakly activates transcriptional
responses with each of the zebrafish ERs in vitro. Transient co-
transfections of zebrafish esr1, esr2a and esr2b and ERE-luciferase were
carried out in Hela cells. Following transfection cells were treated with
increasing doses of either BPA (left graphs) or E2 (right graphs). Note
that E2 activates transcription from each ZfER with an ED 50 of around 1
nM, whereas the ED50s for BPA are 1 μM.
Additional file 7: The BPA phenotype is observed in low dose
alpha1a1 MO. (A) Control embryo with two otoliths. (B) BPA treated
embryo (70 μM, form 6-50 hpf) showing otolith aggregates, (black arrow,
the anterior otolith aggregates are in focus). (C) Low dose of alpha1a1
MO leads to the development of one small otolith (white arrow). (D)
Low dose of alpha1a1 MO injected embryo treated with BPA (70 μM,
form 6-50 hpf) lead to small otoliths formation. Strong otolith aggregates
as seen in B were never observed in the low dose of alpha1a1 MO
injected embryo treated with BPA, however a mild aggregate (4-5
otoliths) as shown in D (arrow) can be observed. All embryos were
observed at 50 hpf.
List of Abbreviations
BPA: bisphenol A; BPC: bisphenol C; BPE: bisphenol E; BPF: bisphenol F;
hpf: hours post ferilization; ER: estrogen receptor; TR: thyroid hormone
receptor.
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